A study in the use of etrolizumab in patients with ulcerative colitis (Eucalyptus)

Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

  • Ulcerative Colitis
Trial Status:

Completed

This trial runs in
Cities
  • Ann Arbor
  • Atlanta
  • Auckland
  • Barcelona
  • Beer Sheva
  • Berlin
  • Bonheiden
  • Budapest
  • Chevy Chase
  • Christchurch
  • Cincinnati
  • Clayton
  • Dunedin
  • Edmonton
  • Fitzroy
  • Gainesville
  • Garran
  • Gent
  • Great Neck
  • Gyor
  • Gyöngyös
  • Haifa
  • Hannover
  • Harrow
  • Hradec Kralove
  • Jerusalem
  • Kiel
  • Leuven
  • Liège
  • London
  • Melbourne
  • Minden
  • Mosonmagyaróvár
  • Nachod
  • Newcastle upon Tyne
  • Ostrava - Poruba
  • Parkville
  • Ramat Gan
  • Rochester
  • San Diego
  • Takapuna
  • Tel Aviv
  • Ulm
  • Woodbridge
  • Zlin
Trial Identifier:

NCT01336465 GP27778 ABS4986g

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This Phase II study is a randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of rhuMAb Beta7 in patients with moderate to severe ulcerative colitis.

      Genentech, Inc. Sponsor
      Phase 2 Phase
      NCT01336465 , ABS4986g , GP27778 Trial Identifier
      placebo, rhuMAb Beta7 Treatments
      Ulcerative Colitis Condition
      Official Title

      Phase II Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

      Eligibility Criteria

      All Gender
      ≥18 Years & ≤ 75 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Diagnosis of moderate to severe ulcerative colitis outpatient
      • Disease duration at time of screening of >/= 12 weeks
      Exclusion Criteria
      • Extensive colonic resection or subtotal or total colectomy
      • Presence of an ileostomy or colostomy
      • Moderate to severe anemia
      • A history or evidence of colonic mucosal dysplasia
      • Pregnant or lactating
      • Significant uncontrolled co-morbidity, such as neurological, cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal (GI) disorders
      • Significant screening ECG abnormalities, including evidence of acute myocardial infarction, complete left bundle branch block, second-degree heart block, or complete heart block
      • Poorly controlled diabetes
      • Impaired renal function
      • Impaired hepatic function in the absence of a diagnosis of primary sclerosing cholangitis
      • Positive tests for antibodies indicating active or prior infection with HIV or hepatitis B (HBV) or C (HCV)
      • Positive screening test for latent mycobacterium tuberculosis (TB) infection
      • Demyelinating disease
      • Received any investigational treatment within 12 weeks prior to initiation of study treatment
      • Previous exposure to rhuMAb Beta7

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now